Chemistry:5-MeO-AET

From HandWiki
Short description: Chemical compound
5-MeO-AET
Clinical data
Other names5-Methoxy-α-ethyltryptamine; 5-MeO-αET; 5-MeO-AET
Routes of
administration
Oral[1]
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
Melting point201 to 203 °C (394 to 397 °F)
  (verify)

5-MeO-αET, also known as 5-methoxy-α-ethyltryptamine, is a psychoactive drug of the tryptamine and α-alkyltryptamine families.[1] It reportedly produces psychedelic and stimulant effects.[1][2]

Use and effects

The dose range of 5-MeO-αET is 50 to 75 mg orally.[1][additional citation(s) needed] 5-MeO-αET produces entactogenic and stimulant effects that can last 4 to 6 hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dose and effects can be expected.{{Citation needed|date=May 2025}

Interactions

Pharmacology

Pharmacodynamics

The pharmacology of 5-MeO-αET has been studied.[3] It is a weak partial agonist of the serotonin 5-HT2A receptor, with a binding affinity (Ki) of 4,073 nM, an EC50 of 166 nM, and an Emax of 34%.[3] For comparison, αET showed 14-fold lower affinity for the receptor than 5-MeO-αET and was inactive as an agonist of the receptor.[3] The individual stereoisomers of 5-MeO-αET and αET were also assessed.[3]

Society and culture

United States

See also

  • Substituted α-alkyltryptamine
  • 4-HO-AMT
  • 4-Methyl-AET
  • 5-Fluoro-AET
  • 5-EtO-AMT
  • 5-MeO-AMT
  • 7-Methyl-AET

References

  1. 1.0 1.1 1.2 1.3 "Basic Pharmacology and Effects". Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. 2003. pp. 67–137. ISBN 978-0-12-433951-4. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=6bb3a7499da8e9852b39cd4db16891147c83f5c6. Retrieved 1 February 2025. 
  2. "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry (Elsevier BV) 39 (2): 221–226. December 2012. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. 
  3. 3.0 3.1 3.2 3.3 Jones, Charles (2024). Exploration of Dopaminergic and Serotonergic Pathways Utilizing Pleiotropic Agents (Thesis). VCU Libraries. doi:10.25772/8c2h-h502. Retrieved 18 May 2025.

Template:Psychedelics